AIM ImmunoTech Inc. Annual Report - How They Did This Year

I’m writing this guide to help you understand how AIM ImmunoTech performed this year. My goal is to turn complex filing data into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

AIM ImmunoTech develops treatments for cancer and immune disorders. Their main drug candidate is Ampligen (rintatolimod). As a clinical-stage biotech company, they do not have products for sale yet. This year, they focused on the Phase 2/3 DURAPB clinical trial for pancreatic cancer and maintained manufacturing standards to support their research.

2. Financial performance

The company lost about $17.5 million in 2024, compared to a $18.2 million loss in 2023. Most of this spending went toward research and development ($10.5 million) and general office expenses ($7.0 million). Because they have no sales, they rely on outside funding to sustain their operations.

3. The impact of fundraising on shareholders

The company frequently raises money to fund its operations. They use a mix of stock sales and "warrants," which are options for investors to buy more stock later. They often use an "At-the-Market" facility to sell shares. While this provides necessary cash, it also causes significant dilution. Every time they issue new shares or warrants, your ownership percentage drops, which often puts downward pressure on the stock price.

4. Financial health and cash runway

As of December 31, 2024, the company had about $5.4 million in cash. To cover costs, they launched a "Rights Offering" in early 2026 to raise $4 million to $5 million. They also issued new warrants to encourage investment. These warrants create a large volume of potential future shares, which adds complexity to the company's financial structure.

5. Key risks

The biggest risk is the dilution mentioned above. Because they have no steady income, they must keep issuing stock to fund research. If they cannot raise money on favorable terms, their research could stop. With a market value near $6.4 million as of mid-2025, the stock is highly volatile. The company has noted that they may require additional funding to continue as a going concern.

6. Competitive positioning

AIM is a small player in a massive industry and relies on outside partners to manage clinical trials and drug production. Their success is "binary": if Ampligen wins FDA approval, the company’s value could change significantly. If not, they face intense competition from large pharmaceutical companies that have more capital and resources to navigate the long FDA approval process.

7. Future outlook

The company is focusing entirely on its clinical pipeline, specifically the completion of the DURAPB trial. They have already started new funding rounds in 2026 to keep their research running. Investors should closely monitor the company’s "cash runway"—how long they can operate before needing more cash—as this will likely lead to further share dilution.

Investor Takeaway: AIM ImmunoTech is a high-risk, speculative investment. Because they have no revenue and rely on selling shares to fund their research, your ownership stake is likely to be diluted over time. This is a "binary" play: the company's future depends almost entirely on the success of the Ampligen clinical trials. Only consider this if you are comfortable with high volatility and the possibility that the company will need to raise more capital to survive.